These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32986384)

  • 1. Relationship of JAK2 (V617F) Allelic Burden with Clinico- Haematological Manifestations of Philadelphia-Negative Myeloproliferative Neoplasms.
    Yow KS; Liu X; Chai CN; Tung ML; Yan B; Christopher D; Ong KH; Ooi MG
    Asian Pac J Cancer Prev; 2020 Sep; 21(9):2805-2810. PubMed ID: 32986384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR.
    Lu Y; Lin L; Lin J; Wu B; Cai G; Wang X; Ma X
    Ann Hematol; 2024 Sep; 103(9):3553-3562. PubMed ID: 39043913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
    Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
    Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
    Ha JS; Kim YK; Jung SI; Jung HR; Chung IS
    Ann Lab Med; 2012 Nov; 32(6):385-91. PubMed ID: 23130336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.
    Chatambudza M; Skhosana L; Ketseoglou I; Wiggill T
    Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.
    Bang SM; Lee JS; Ahn JY; Lee JH; Hyun MS; Kim BS; Park MR; Chi HS; Kim HY; Kim HJ; Lee MH; Kim H; Won JH; Yoon HJ; Oh DY; Nam EM; Bae SH; Kim BK;
    Thromb Haemost; 2009 Mar; 101(3):547-51. PubMed ID: 19277418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low
    Makarik TV; Abdullaev AO; Nikulina EE; Treglazova SA; Stepanova EE; Subortseva IN; Kovrigina AM; Melikyan AL; Kulikov SM; Sudarikov AB
    Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33921387
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs.
    Link-Lenczowska D; Pallisgaard N; Cordua S; Zawada M; Czekalska S; Krochmalczyk D; Kanduła Z; Sacha T
    Ann Hematol; 2018 Dec; 97(12):2299-2308. PubMed ID: 30056580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.
    Ohyashiki JH; Yoneta M; Hisatomi H; Iwabuchi T; Umezu T; Ohyashiki K
    BMC Med Genet; 2012 Jan; 13():6. PubMed ID: 22251709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms].
    Kim JT; Cho YG; Choi SI; Lee YJ; Kim HR; Jang SJ; Moon DS; Park YJ; Park G
    Korean J Lab Med; 2010 Dec; 30(6):567-74. PubMed ID: 21157140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
    Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
    Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.
    Yoo EH; Jang JH; Park KJ; Gwak GY; Kim HJ; Kim SH; Kim DK
    Int J Lab Hematol; 2011 Oct; 33(5):471-6. PubMed ID: 21435189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Wu Z; Zhang X; Xu X; Chen Y; Hu T; Kang Z; Li S; Wang H; Liu W; Ma X; Guan M
    J Hematol Oncol; 2014 Jul; 7():48. PubMed ID: 25023898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms.
    Kim HR; Choi HJ; Kim YK; Kim HJ; Shin JH; Suh SP; Ryang DW; Shin MG
    PLoS One; 2013; 8(1):e52518. PubMed ID: 23349688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms.
    Demiriz IŞ; Kazanci MH; Menfaatli E; Jafari-Gharabaghlou D; Zarghami N
    Mol Biol Rep; 2023 Jul; 50(7):5687-5695. PubMed ID: 37209326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation.
    Haunstrup LM; Ebbesen LH; Hansen M; Severinsen MT; Aggerholm A
    Exp Hematol; 2018 Dec; 68():62-65. PubMed ID: 30292681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
    Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
    Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of JAK2 V617F Allele Burden by Using the QuantStudio™ 3D Digital PCR System.
    Kinz E; Muendlein A
    Methods Mol Biol; 2018; 1768():257-273. PubMed ID: 29717448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.